Concepedia

Lorcan Sherry

LS

Statistics

Publications

5

Citations

256

H-Index

5

Active since

1998

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Edinburgh

NHS Lanarkshire

Lorcan Sherry is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in ligand binding, medicinal chemistry, and pharmacology.

Publications per year

1998–2016

5

Publications

5

Differential Effects of Angiotensin II on Cardiac Cell Proliferation and Intramyocardial Perivascular Fibrosis In Vivo

Pauline E. McEwan, Gillian A. Gray, Lorcan Sherry et al. · Circulation · 1998 · 172 citations

, , +10

Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors

Peter C. Ray, Jane Wright, Julia Adam et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 30 citations · Full text

, , +14

Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors

Peter C. Ray, Jane Wright, Julia Adam et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 19 citations · Full text

, , +12

Immunolocalisation and activity of DDAH I and II in the heart and modification post-myocardial infarction

Gillian A. Gray, Mark Patrizio, Lorcan Sherry et al. · Acta Histochemica · 2009 · 18 citations

, , +10

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Casey R. Ager, Matthew J. Reilley, Courtney Nicholas et al. · Journal for ImmunoTherapy of Cancer · 2016 · 17 citations · Full text

, , +17

1–5 of 5